SCRS Launches Eagle Insights Dashboard To Score Sponsor And CRO Site Relationships
The Catalyst Brief
Coverage
Medical Technology
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
Latest
EY Says Medtech Reached About $650 Billion In 2025 Revenue, With Growth Concentrated In Commercial Leaders
The Catalyst Brief
Labcorp Launches Thrive 5 Health Test, Pairing Five Biomarkers With Behavior-Change Guidance
The Catalyst Brief
Epic Launches Prescription Marketplace, Adding Cash And Insurance Drug Price Comparisons For Summer 2027
The Catalyst Brief
Most read
FDA Flags Edwards Lifesciences SAPIEN M3 Delivery Lots After Balloon Bursts, With One Death And One Serious Injury Reported
The Catalyst Brief
Abbott Wins FDA Clearance For CardioMEMS App Upgrade, Adding At-Home Pressure Visibility
The Catalyst Brief
Agilent Buys Proscia For $240 Million Upfront, Extending Its Push Into Digital Pathology
The Catalyst Brief
Brain-Computer Interface Breakthrough Empowers People with Paralysis to Type Using Their Minds
The Catalyst Brief
More in this beat
Oct 17, 2026FDA Flags Edwards Lifesciences SAPIEN M3 Delivery Lots After Balloon Bursts, With One Death And One Serious Injury Reported
Edwards told customers on Oct. 5 to remove four specific lots from locations where they are used or sold. The event is an early commercial and safety setback for a system that received FDA approval last December.
The Catalyst Brief
Oct 14, 2026Agilent Buys Proscia For $240 Million Upfront, Extending Its Push Into Digital Pathology
Agilent Technologies said it will buy digital pathology software company Proscia for $240 million upfront, plus an additional $30 million tied to future performance milestones. The deal gives Agilent control of Concentriq, a platform used to manage pathology images, data and workflows across more than 4,000 laboratories, hospitals and pharma companies.
The Catalyst Brief
Oct 14, 2026Insulet Expands Omnipod Discover To Full U.S. Release After 15,000-User Limited Rollout
The launch broadens Insulet’s offering around Omnipod 5 beyond automated insulin delivery itself and into the software layer that can shape adherence, clinician engagement and product stickiness. Early adoption figures from the limited program suggest Insulet sees data interpretation, not just data generation, as a competitive feature in diabetes technology.
The Catalyst Brief
Oct 10, 2026BD Names Ferass Abuzaina To Lead Surgery Business, Signaling An Internal-Operator Bet
Abuzaina most recently served as Worldwide VP/GM, Advanced Repair and Reconstruction, within Surgery, and will report to Peter Menziuso, Executive Vice President and President of BD’s Interventional segment. The move points to continuity rather than a strategic reset in a business BD says is entering its next chapter of growth.
The Catalyst Brief
Oct 6, 2026Abbott Wins FDA Clearance For CardioMEMS App Upgrade, Adding At-Home Pressure Visibility
The newly cleared features connect Abbott’s implanted pulmonary artery pressure sensor to the CardioGuide HF App, giving CardioMEMS patients direct access to their readings. For Abbott, the update is less about a new sensor than about making an existing monitoring system more actionable for patients and care teams.
The Catalyst Brief
Oct 2, 2026Abbott Launches SimpleScreen CRC In The U.S., Adding A Blood-Based Option For Unscreened Average-Risk Adults
SimpleScreen CRC is designed for adults who decline or do not complete preferred colorectal cancer screening options. The commercial bet is that an additional blood-draw pathway can convert some of the large unscreened population into completed tests, even as colonoscopy remains the most reliable screening method named in the source.
The Catalyst Brief
Sep 29, 2026DreaMed Wins FDA Clearance For MODI, Expanding Insulin Automation To More Complex Type 2 Regimens
MODI is cleared to analyze continuous glucose monitoring patterns and insulin use, then generate personalized dose recommendations after a physician prescribes the app. For DreaMed, the strategic value is not novelty alone but a wider addressable population inside insulin-treated Type 2 diabetes, where treatment changes are often delayed between primary care visits.
The Catalyst Brief
Sep 23, 2026Cordis Wins FDA Approval For Selution SLR DEB, Opening A U.S. Sirolimus Balloon Option In Coronary ISR
The approval covers a device designed to deliver sustained sirolimus therapy for coronary in-stent restenosis without placing a permanent implant. For Cordis, the decision also starts to validate the MedAlliance acquisition strategy that expanded its drug-eluting balloon portfolio.
The Catalyst Brief
Sep 19, 2026Medtronic Wins FDA Clearance For LigaSure RAS Maryland Jaw With Hugo, Expanding U.S. Robotic Surgery Workflow
The clearance lets Medtronic pair the Hugo robotic-assisted surgery system in the U.S. with a LigaSure instrument already established in open and laparoscopic surgery. Strategically, the move is less about novelty than about making Hugo more usable in real operating-room workflows as competition in robotic surgery increases.
The Catalyst Brief
Sep 13, 2026Powerful Medical Wins De Novo EKG Classification, Opening A Higher-Evidence AI Triage Route
Powerful Medical’s model is aimed at a harder, time-sensitive use case: helping direct chest-pain patients to the right care when a coronary artery is completely blocked. In a market crowded with AI tools for screening and prevention, the de novo decision signals that acute-care algorithms may need stronger evidence and clearer regulatory differentiation.
The Catalyst Brief
Sep 13, 2026GE HealthCare Eyes Up To $1 Billion Sofie Biosciences Deal, Expanding Imaging Chemicals Reach
The Financial Times reported, citing people familiar with the matter, that GE HealthCare could announce a Sofie Biosciences acquisition as soon as this coming week. Neither company has commented on the report. Strategically, the move would strengthen GE’s pharma diagnostics business as the company reshapes its imaging operations and reviews other units.
The Catalyst Brief
Sep 2, 2026Medtronic Recalls Bravo CF Capsule Delivery Devices After 184 Serious Injuries, Reviving A Prior Failure Mode
The FDA issued an early alert after Medtronic sent customers an August 6 letter about the problem. The event matters commercially because it affects a wireless reflux-monitoring device already tied to a June 2025 recall, even though the company said the underlying cause is different this time.
The Catalyst Brief
Other beats
AI in Drug Discovery
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Biopharmaceutical Industry
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Biotech Innovation
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Healthcare Investment
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Regulatory & Policy
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.